Innovent Biologics Current Assets

Innovent Biologics (IVBXF) currently reports a current assets of $25B as of June 2026. That compares with $13B in the prior-year period — up 90.8% year over year. Use the charts on this page to explore Innovent Biologics's current assets history and peer comparisons.

Innovent Biologics's current assets increased from $13B to $25B — a 90.8% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Innovent Biologics reported $25B in current assets as of June 2026. That compares with $13B in the prior-year period — up 90.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current assets of $25B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Innovent Biologics, and consider following IVBXF for alerts when major investors trade the stock.

Innovent Biologics is classified in the Healthcare sector. On current assets, it currently shows $25B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IVBXF with unrelated industries.